Selective activation of Nrf2 using synthetic triterpenoids, such as CCDO-IM and CCDO-Me [273], targeting iNOS with nitroaspirin [274], use of N-hydroxy-nor-l-arginine (nor-NOHA) [150], uric acid [275], and bardoxolone methyl [276] have been shown to inhibit the production of these immunosuppressive molecules, thereby restoring immune function and inhibiting tumor progression. The gene discussed is NOS2; the disease is neoplasm.